English
|
Español
English
|
Español
Insurance
Marketing
Pharmaceuticals
Technology/Innovation
Regulatory
Community
China Food And Drug Administration
Robert Hadley
| May 14, 2017
Bristol-Myers Squibb dual-drug treatment for hepatitis C gains China approval
Gene Johnson
| Mar 24, 2017
China approves Xeljanz to treat moderate to severe rheumatoid arthritis
Trending
+
Pharmaceuticals
Patient Daily
| Jun 5, 2025
Exon 20 Group questions effectiveness of 340B drug program
+
Pharmaceuticals
Patient Daily
| Jun 9, 2025
Director of Public Affairs of PhRMA: ‘There is also evidence that 340B is harming state and federal budgets’
+
Pharmaceuticals
Patient Daily
| Jun 5, 2025
New study identifies indicators for HER2+ breast cancer therapy response
+
Pharmaceuticals
Patient Daily
| Jun 4, 2025
American Lung Association offers guidance on Saharan dust impact on health
